<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Med</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Med</journal-id><journal-id journal-id-type="pmc-domain-id">3900</journal-id><journal-id journal-id-type="pmc-domain">kme</journal-id><journal-title-group><journal-title>Kidney Medicine</journal-title></journal-title-group><issn pub-type="epub">2590-0595</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12221723</article-id><article-id pub-id-type="pmcid-ver">PMC12221723.1</article-id><article-id pub-id-type="pmcaid">12221723</article-id><article-id pub-id-type="pmcaiid">12221723</article-id><article-id pub-id-type="pmid">40613015</article-id><article-id pub-id-type="doi">10.1016/j.xkme.2025.101022</article-id><article-id pub-id-type="pii">S2590-0595(25)00058-5</article-id><article-id pub-id-type="publisher-id">101022</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Posterior Reversible Encephalopathy Syndrome in Chronic Kidney Disease: Incidence, Outcomes, and Risk Factors in a National Cohort</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>He</surname><given-names initials="M">Mingyue</given-names></name><email>mingyue.he@tuhs.temple.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#8727;</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Gillespie</surname><given-names initials="A">Avrum</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><label>1</label>Department of Internal Medicine, Temple University Hospital, Philadelphia, PA</aff><aff id="aff2"><label>2</label>Section of Nephrology, Hypertension and Kidney Transplantation, Lewis Katz School of Medicine at Temple University, Philadelphia, PA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8727;</label><bold>Address for Correspondence:</bold> Mingyue He, MD, Department of Internal Medicine, Temple University Hospital, 3401 N. Broad St, 8th Floor, Philadelphia, PA 19140. <email>mingyue.he@tuhs.temple.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>5</month><year>2025</year></pub-date><volume>7</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">490941</issue-id><elocation-id>101022</elocation-id><pub-history><event event-type="pmc-release"><date><day>08</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>03</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-04 09:25:24.740"><day>04</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><sec><title>Rationale &amp; Objective</title><p>Posterior reversible encephalopathy syndrome (PRES) is an acute neurological condition that, if untreated, can result in severe complications, such as intracerebral hemorrhage. Patients with chronic kidney disease (CKD) are at an increased risk of developing PRES; however, it is unclear whether this risk is primarily driven by comorbid conditions or if renal dysfunction itself is an independent risk factor. This study aimed to evaluate the incidence, outcomes, and resource utilization of PRES across CKD stages compared with patients without kidney disease.</p></sec><sec><title>Study Design</title><p>A retrospective study using the Nationwide Inpatient Sample Database.</p></sec><sec><title>Setting &amp; Participants</title><p>Adult patients nonelectively admitted with PRES from 2016 to 2019.</p></sec><sec><title>Exposures</title><p>Different stages of CKD versus no kidney disease</p></sec><sec><title>Outcomes</title><p>All-cause in-hospital mortality, Incidence of PRES hospitalizations, in-hospital morbidity (intracerebral hemorrhage, ischemic stroke, brain herniation, and status epilepticus), and health care resource utilization (length of hospital stay and total hospitalization charges)</p></sec><sec><title>Analytical Approach</title><p>Multivariate logistic and linear regression analyses were conducted using survey design methods.</p></sec><sec><title>Results</title><p>The cohort included 12,605 patients, representing 0.014% of all admissions. PRES incidence increased from 0.013% in 2016 to 0.015% in 2019 (<italic toggle="yes">P</italic>&#160;=&#160;0.01) and demonstrated a dose-response relationship with CKD stage progression. Key risk factors for PRES included female sex, White race, hypertension, metastatic cancer, solid organ transplantation, rheumatologic disorders, substance use disorders, carotid artery stenosis, migraines, and cerebral atherosclerosis. Kidney failure (KF) was strongly associated with in-hospital mortality (aOR 5.12, 95% CI, 2.09-12.53, <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001). The length of stay, total hospitalization charge, and rates of neurological complications were similar between CKD/KF and patients without kidney disease.</p></sec><sec><title>Limitations</title><p>The use of administrative data limits access to detailed clinical information. Residual confounding factors remain possible.</p></sec><sec><title>Conclusions</title><p>This is the largest study to date on PRES in CKD populations. CKD is strongly associated with PRES, with a dose-response relationship, and KF is an independent risk factor for in-hospital mortality, emphasizing the need for heightened clinical vigilance in this population.</p></sec></abstract><abstract abstract-type="plain-language-summary" id="abssec0055"><title>Plain-Language Summary</title><p>Posterior Reversible Encephalopathy Syndrome (PRES) is a serious brain condition that can cause seizures, confusion, and even death if not recognized and treated in time. However, it is often overlooked because its symptoms can be vague. While PRES is commonly linked to high blood pressure and immune system diseases, its connection to chronic kidney disease (CKD) has been unclear. This study used a large national database to examine how often PRES occurs in people with CKD and its impact on their health. The findings show that the risk of PRES increases as kidney disease worsens, with patients in kidney failure being the most vulnerable. These results highlight the need for early recognition and close monitoring of patients with CKD to improve their care.</p></abstract><kwd-group id="kwrds0010"><title>Index Words</title><kwd>Posterior reversible encephalopathy syndrome</kwd><kwd>nationwide inpatient sample</kwd><kwd>chronic kidney disease</kwd><kwd>kidney failure</kwd><kwd>end-stage kidney disease</kwd><kwd>In-hospital mortality</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">Posterior reversible encephalopathy syndrome (PRES), first described in 1996, is a neurologic condition characterized by seizures, headaches, altered mental status, and visual disturbances. Neuroimaging typically shows bilateral vasogenic edema, predominantly involving the parietal and occipital lobes.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Although PRES is generally considered a reversible condition with timely diagnosis and appropriate management, it is often underrecognized. Delayed identification or treatment can lead to permanent neurological damage and severe complications, such as cerebral hemorrhage, cerebellar herniation, refractory status epilepticus, and death. The underling pathophysiology of PRES remains unclear, but cerebral blood flow dysregulation and endothelial dysfunction are believed to play key roles.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref></p><p id="p0015">PRES most commonly occurs in the context of acute, severe hypertension or sudden, moderate elevations in blood pressure from the baseline. Although accelerated hypertension is a common precipitant, 20%-30% PRES cases occur in normotensive or hypotensive patients, particularly when triggered by medications or systemic conditions unrelated to hypertension.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref> Nearly half of all patients with PRES have a history of rheumatologic or autoimmune disorders,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> with immunosuppressive or chemotherapeutic agents commonly implicated.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> Given the associations between kidney disease and risk factors, such as hypertension, autoimmune diseases, and immunosuppressive therapies, a higher incidence of PRES might be expected in patients with kidney disease. However, the current evidence is limited, primarily based on case series, and lacks comprehensive systematic investigation.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref></p><p id="p0020">Emerging data suggest that acute and chronic kidney diseases (CKD) are present in up to 57% of patients with PRES, indicating their potential role as significant risk factors.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> However, these findings are derived from studies with small sample sizes, leaving it unclear whether renal dysfunction independently predisposes individuals to PRES or if this association is mediated by coexisting conditions such as hypertension or autoimmune disorders.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Furthermore, the impact of CKD progression on PRES incidence and outcomes remains poorly understood.</p><p id="p0025">With the growing global burden of CKD, it is increasingly important to understand its role in conditions like PRES. Despite its clinical relevance, no large-scale studies have systematically examined the incidence, in-hospital mortality, morbidity, and health care resource utilization associated with PRES in patients with CKD. To address this gap, our study leverages data from the largest publicly available national inpatient database in the United States to assess the incidence and outcomes of PRES hospitalizations across various CKD stages and identify risk factors for PRES and adverse outcomes.</p><sec id="sec1"><title>Methods</title><sec id="sec1.1"><title>Data Source</title><p id="p0030">This retrospective observational study used the Nationwide Inpatient Sample (NIS), the largest publicly available all-payer inpatient database in the United States, maintained by the Healthcare Cost and Utilization Project and supported by the Agency for Healthcare Research and Quality.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> The NIS provides a nationally representative 20% sample of nonfederal short-term care hospital discharges, with discharge data weighted for national estimates. It includes patient-level and hospital-level data, capturing up to 40 diagnoses and 25 procedures per patient, coded using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM).</p><p id="p0035">For this analysis, data from 2016 to 2019 were included. This timeframe represents the most recent period after the introduction of a specific ICD-10 code for PRES in 2015 and avoids potential confounding effects of the COVID-19 pandemic and its aftermath on PRES incidence and outcomes.</p></sec><sec id="sec1.2"><title>Ethic Statement</title><p id="p0040">Institutional review board approval was not required for this study due to the retrospective design and the use of deidentified data. The study was conducted in strict compliance with the data-use agreements of the NIS.</p></sec><sec id="sec1.3"><title>Study Subjects</title><p id="p0045">We identified patients hospitalized with a principal diagnosis of PRES using the ICD-10-CM code I67.83, whose validity has been established in previous studies with a sensitivity of 100% (95% CI, 86.8%-100%) and specificity of 88.2% (95% CI, 72.6%-96.7%).<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Patients younger than 18 years and those admitted electively were excluded to focus on urgent admissions. Patients were categorized into 6 groups based on renal status: CKD stage 3, CKD stage 4, CKD stage 5, kidney failure (KF: end-stage kidney disease), non-kidney disease (NKD: no pre-existing renal conditions), and Other (patients with CKD stages 1, 2, or unspecified CKD). Data extraction was conducted using ICD-10-CM codes, as detailed in <xref rid="appsec1" ref-type="sec">Table S1</xref>. Because of the high heterogeneity in the &#8220;Other&#8221; group, primarily driven by unspecified CKD cases, this category was excluded from subsequent comparative statistical analyses.</p><p id="p0050">The incidence of PRES hospitalizations was defined as the number of hospitalizations for PRES divided by the total number of hospitalizations for all causes. To calculate this incidence, all nonelectively hospitalized patients aged&#160;&gt;18 years were identified and categorized into the same 6 groups as previously described.</p></sec><sec id="sec1.4"><title>Study Outcomes and Variables</title><p id="p0055">The primary outcome was all-cause in-hospital mortality. Secondary outcomes included: (1) the incidence of PRES hospitalizations across groups; (2) in-hospital morbidity, encompassing intracranial hemorrhage (ICH), ischemic stroke, brain herniation and status epilepticus; and (3) health care resource utilization, evaluated by length of hospital stay (LOS) and total hospitalization charges.</p><p id="p0060">To minimize confounding, various variables were extracted and analyzed, including patient demographics (age, sex, and race), socioeconomic indicators (median income by zip code and primary payer status), and hospital characteristics (bed size, teaching status, and geographic location). Comorbid conditions evaluated included diabetes, hypertension, obesity, congestive heart failure, coronary artery disease, atrial fibrillation, valvular heart disease, chronic pulmonary and liver diseases, nonmetastatic and metastatic cancers, history of solid organ transplantation, history of transient ischemic attack (TIA) and cerebral infarction, dementia, carotid artery stenosis, cerebral atherosclerosis, migraine, rheumatologic disorders, and preeclampsia or eclampsia. Additionally, substance use (tobacco, alcohol, and drug abuse) was assessed. The overall burden of comorbid conditions was quantified using the Charlson Comorbidity Index (CCI). A comprehensive list of diagnostic codes is provided in <xref rid="appsec1" ref-type="sec">Table S1</xref>.</p></sec><sec id="sec1.5"><title>Statistical Analysis</title><p id="p0065">Statistical analyses were performed using Stata/MP 18.0 (StataCorp LLC). The NIS dataset employs a complex sampling design involving stratification, clustering, and weighting. Accordingly, data were processed as survey data and adjusted using the discharge-level weight variable.</p><p id="p0070">Univariable regression analysis was initially performed to calculate unadjusted odds ratios for the primary and secondary outcomes (Model 1). Multivariable regression analyses were subsequently conducted to adjust for potential confounders. Logistic regression models were used for binary outcomes, whereas linear regression models were applied to continuous outcomes. Adjusted odds ratios were reported for binary outcomes, and adjusted mean differences were calculated for continuous outcomes. To address potential multicollinearity, the Variance Inflation Factor (VIF) was assessed, and variables with a Variance Inflation Factor greater than 5 were excluded from the final models. The variable preeclampsia or eclampsia was excluded from both univariate and multivariate analyses due to its absence (frequency of 0) among patients with CKD stages 3-5 and KF. In addition to Model 1 (univariate analysis), 3 multivariable models were developed. Model 2 adjusted for demographic factors, while Model 3 included adjustments for demographics, socioeconomic indicators, and hospital characteristics. Model 4 incorporated comorbid conditions in addition to the adjustments in Model 3 and included only variables that demonstrated an association with outcomes at a <italic toggle="yes">P</italic>&#160;&lt;&#160;0.2 in univariate analysis. Statistical significance was defined as a 2-sided <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05.</p></sec></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Patient and Hospital Characteristics</title><p id="p0075"><xref rid="fig1" ref-type="fig">Fig 1</xref> depicts the flow diagram for the selection of the study cohort. From 2016 to 2019, 12,605 adult patients were nonelectively hospitalized with a principal diagnosis of PRES. Among these, 1,145 patients (9.1%) had CKD stage 3, 420 (3.3%) had CKD stage 4, 75 (0.6%) had CKD stage 5, and 1,810 (14.4%) had KF. The remaining 8,235 patients (65.3%) had no documented NKD.<fig id="fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram of study selection. Patients were identified from the Nationwide Inpatient Sample (NIS) database (2016-2019) using the ICD-10-CM code. PRES, posterior reversible encephalopathy syndrome; NKD, no pre-existing kidney disease; CKD, chronic kidney disease; KF, kidney failure (end-stage kidney disease). &#8727;Others: include patients with a diagnosis of CKD stage 1, CKD stage 2, and unspecified CKD stages.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0080"><xref rid="tbl1" ref-type="table">Table 1</xref> summarizes patient and hospital characteristics. The mean age of the cohort was 57.5&#160;&#177;&#160;0.3 years, with female patients comprising 71.5% of the sample. Most hospitalizations involved White patients (72.5%), followed by Black (17.8%), and Hispanic (5.9%) individuals. The Southern region accounted for the highest proportion of PRES admissions (42.8%), with additional regional details available in <xref rid="appsec1" ref-type="sec">Table S2</xref>. Medicare was the primary payer for 52.2% of admissions, and 81.6% of patients received care at urban teaching hospitals.<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Baseline Characteristics of Adult Patients Nonelectively Hospitalized for PRES</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Characteristics</th><th colspan="1" rowspan="1">Total N&#160;=&#160;12,605</th><th colspan="1" rowspan="1">NKD n&#160;=&#160;8,235</th><th colspan="1" rowspan="1">CKD 3 n&#160;=&#160;1,145</th><th colspan="1" rowspan="1">CKD4&#160;n&#160;=&#160;420</th><th colspan="1" rowspan="1">CKD5&#160;n&#160;=&#160;76</th><th colspan="1" rowspan="1">KF n&#160;=&#160;1,810</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Age (mean&#160;&#177;&#160;SD)</td><td colspan="1" rowspan="1">57.5&#160;&#177;&#160;0.3</td><td colspan="1" rowspan="1">59.0&#160;&#177;&#160;0.3</td><td colspan="1" rowspan="1">63.0&#160;&#177;&#160;1.0</td><td colspan="1" rowspan="1">59.2&#160;&#177;&#160;1.9</td><td colspan="1" rowspan="1">50.5&#160;&#177;&#160;5.1</td><td colspan="1" rowspan="1">46.8&#160;&#177;&#160;0.9</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Female n (%)</td><td colspan="1" rowspan="1">9,018 (71.5%)</td><td colspan="1" rowspan="1">6,193 (75.2%)</td><td colspan="1" rowspan="1">802 (70.0%)</td><td colspan="1" rowspan="1">273 (65.1%)</td><td colspan="1" rowspan="1">56 (73.3%)</td><td colspan="1" rowspan="1">1,115 (61.6%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Race n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;White</td><td colspan="1" rowspan="1">9,144 (72.5%)</td><td colspan="1" rowspan="1">6,637 (80.6%)</td><td colspan="1" rowspan="1">802 (70.0%)</td><td colspan="1" rowspan="1">215 (51.3%)</td><td colspan="1" rowspan="1">38 (50.0%)</td><td colspan="1" rowspan="1">842 (46.5%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Black</td><td colspan="1" rowspan="1">2,240 (17.8%)</td><td colspan="1" rowspan="1">976 (11.9%)</td><td colspan="1" rowspan="1">250 (21.8%)</td><td colspan="1" rowspan="1">147 (35.0%)</td><td colspan="1" rowspan="1">16 (21.4%)</td><td colspan="1" rowspan="1">649 (35.8%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Hispanic</td><td colspan="1" rowspan="1">739 (5.9%)</td><td colspan="1" rowspan="1">322 (3.9%)</td><td colspan="1" rowspan="1">62 (5.4%)</td><td colspan="1" rowspan="1">32 (7.5%)</td><td colspan="1" rowspan="1">5 (7.1%)</td><td colspan="1" rowspan="1">230 (12.7%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Asian or Pacific Islander</td><td colspan="1" rowspan="1">139 (1.1%)</td><td colspan="1" rowspan="1">88 (1.1%)</td><td colspan="1" rowspan="1">16 (1.4%)</td><td colspan="1" rowspan="1">5 (1.2%)</td><td colspan="1" rowspan="1">11 (14.3%)</td><td colspan="1" rowspan="1">16 (0.9%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Native American</td><td colspan="1" rowspan="1">47 (0.4%)</td><td colspan="1" rowspan="1">16 (0.2%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">26 (1.5%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Others</td><td colspan="1" rowspan="1">291 (2.3%)</td><td colspan="1" rowspan="1">187 (2.3%)</td><td colspan="1" rowspan="1">16 (1.4%)</td><td colspan="1" rowspan="1">21 (5.0%)</td><td colspan="1" rowspan="1">5 (7.2%)</td><td colspan="1" rowspan="1">47 (2.6%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="7" rowspan="1">Median household income for patient&#8217;s zip code n (%)</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;$1-$49,999</td><td colspan="1" rowspan="1">3,967 (31.5%)</td><td colspan="1" rowspan="1">2,353 (28.6%)</td><td colspan="1" rowspan="1">373 (32.6%)</td><td colspan="1" rowspan="1">177 (42.2%)</td><td colspan="1" rowspan="1">25 (33.3%)</td><td colspan="1" rowspan="1">721 (39.8%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;$50,000-$64,999</td><td colspan="1" rowspan="1">3,403 (27.0%)</td><td colspan="1" rowspan="1">2,363 (28.7%)</td><td colspan="1" rowspan="1">298 (26.0%)</td><td colspan="1" rowspan="1">132 (31.3%)</td><td colspan="1" rowspan="1">10 (13.3%)</td><td colspan="1" rowspan="1">368 (20.3%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;$65,000&#8211;$85,999</td><td colspan="1" rowspan="1">3,210 (25.5%)</td><td colspan="1" rowspan="1">2,130 (25.9%)</td><td colspan="1" rowspan="1">293 (25.6%)</td><td colspan="1" rowspan="1">61 (14.5%)</td><td colspan="1" rowspan="1">15 (20.0%)</td><td colspan="1" rowspan="1">496 (27.4%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;$86,000 or more</td><td colspan="1" rowspan="1">2,024 (16.1%)</td><td colspan="1" rowspan="1">1,389 (16.9%)</td><td colspan="1" rowspan="1">182 (15.9%)</td><td colspan="1" rowspan="1">51 (12.1%)</td><td colspan="1" rowspan="1">25 (33.3%)</td><td colspan="1" rowspan="1">225 (12.4%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="7" rowspan="1">Insurance status n (%)</td><td colspan="1" rowspan="1">0.045</td></tr><tr><td colspan="1" rowspan="1">&#160;Medicare</td><td colspan="1" rowspan="1">6,582 (52.2%)</td><td colspan="1" rowspan="1">4,122 (50.1%)</td><td colspan="1" rowspan="1">650 (56.8%)</td><td colspan="1" rowspan="1">241 (57.3%)</td><td colspan="1" rowspan="1">30 (40.0%)</td><td colspan="1" rowspan="1">1,015 (56.1%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medicaid</td><td colspan="1" rowspan="1">2,460 (19.5%)</td><td colspan="1" rowspan="1">1,577 (19.2%)</td><td colspan="1" rowspan="1">191 (16.7%)</td><td colspan="1" rowspan="1">87 (20.7%)</td><td colspan="1" rowspan="1">25 (33.3%)</td><td colspan="1" rowspan="1">405 (22.4%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Private including HMO</td><td colspan="1" rowspan="1">2,999 (23.8%)</td><td colspan="1" rowspan="1">2,135 (25.9%)</td><td colspan="1" rowspan="1">258 (22.5%)</td><td colspan="1" rowspan="1">61 (14.6%)</td><td colspan="1" rowspan="1">20 (26.7%)</td><td colspan="1" rowspan="1">338 (18.7%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Self-pay</td><td colspan="1" rowspan="1">563 (4.5%)</td><td colspan="1" rowspan="1">395 (4.8%)</td><td colspan="1" rowspan="1">46 (4.0%)</td><td colspan="1" rowspan="1">31 (7.4%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">51 (2.8%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="7" rowspan="1">Hospital bed size n (%)</td><td colspan="1" rowspan="1">0.10</td></tr><tr><td colspan="1" rowspan="1">&#160;Small</td><td colspan="1" rowspan="1">1,370 (10.9%)</td><td colspan="1" rowspan="1">965 (11.7%)</td><td colspan="1" rowspan="1">106 (9.3%)</td><td colspan="1" rowspan="1">25 (6.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">170 (9.4%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medium</td><td colspan="1" rowspan="1">2,980 (23.6%)</td><td colspan="1" rowspan="1">2,045 (24.8%)</td><td colspan="1" rowspan="1">242 (21.1%)</td><td colspan="1" rowspan="1">111 (26.5%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">400 (22.1%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Large</td><td colspan="1" rowspan="1">8,255 (65.5%)</td><td colspan="1" rowspan="1">5,225 (63.5%)</td><td colspan="1" rowspan="1">797 (69.6%)</td><td colspan="1" rowspan="1">283 (67.5%)</td><td colspan="1" rowspan="1">71 (93.3%)</td><td colspan="1" rowspan="1">1,240 (68.5%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="7" rowspan="1">Hospital location/teaching status n (%)</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">&#160;Rural</td><td colspan="1" rowspan="1">415 (3.3%)</td><td colspan="1" rowspan="1">305 (3.7%)</td><td colspan="1" rowspan="1">25 (2.2%)</td><td colspan="1" rowspan="1">20 (4.8%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">40 (2.2%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Urban nonteaching</td><td colspan="1" rowspan="1">1,905 (15.1%)</td><td colspan="1" rowspan="1">1,326 (16.1%)</td><td colspan="1" rowspan="1">207 (18.1%)</td><td colspan="1" rowspan="1">40 (9.6%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">205 (11.3%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Urban teaching</td><td colspan="1" rowspan="1">10,284 (81.6%)</td><td colspan="1" rowspan="1">6,600 (80.2%)</td><td colspan="1" rowspan="1">913 (79.7%)</td><td colspan="1" rowspan="1">360 (85.6%)</td><td colspan="1" rowspan="1">76 (100.0%)</td><td colspan="1" rowspan="1">1,565 (86.5%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="7" rowspan="1">Hospital region n (%)<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">&#160;Northeast</td><td colspan="1" rowspan="1">2,155 (17.1%)</td><td colspan="1" rowspan="1">1,530 (18.6%)</td><td colspan="1" rowspan="1">131 (11.5%)</td><td colspan="1" rowspan="1">25 (6.0%)</td><td colspan="1" rowspan="1">20 (26.7%)</td><td colspan="1" rowspan="1">270 (14.9%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Midwest</td><td colspan="1" rowspan="1">2,750 (21.8%)</td><td colspan="1" rowspan="1">1,715 (20.8%)</td><td colspan="1" rowspan="1">277 (24.2%)</td><td colspan="1" rowspan="1">132 (31.3%)</td><td colspan="1" rowspan="1">20 (26.7%)</td><td colspan="1" rowspan="1">405 (22.4%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;South</td><td colspan="1" rowspan="1">5,400 (42.8%)</td><td colspan="1" rowspan="1">3,575 (43.4%)</td><td colspan="1" rowspan="1">459 (40.1%)</td><td colspan="1" rowspan="1">182 (43.4%)</td><td colspan="1" rowspan="1">30 (40.0%)</td><td colspan="1" rowspan="1">780 (43.1%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;West</td><td colspan="1" rowspan="1">2,300 (18.3%)</td><td colspan="1" rowspan="1">1,415 (17.2%)</td><td colspan="1" rowspan="1">277 (24.2%)</td><td colspan="1" rowspan="1">81 (19.3%)</td><td colspan="1" rowspan="1">5 (6.6%)</td><td colspan="1" rowspan="1">355 (19.6%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="7" rowspan="1">Charlson Comorbidity Index (CCI) n (%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">2,560 (20.3%)</td><td colspan="1" rowspan="1">2,560 (31.1%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2</td><td colspan="1" rowspan="1">2,380 (18.9%)</td><td colspan="1" rowspan="1">2,380 (28.9%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#8805;3</td><td colspan="1" rowspan="1">7,665 (60.8%)</td><td colspan="1" rowspan="1">3,295 (40.0%)</td><td colspan="1" rowspan="1">1,145 (100.0%)</td><td colspan="1" rowspan="1">420 (100.0%)</td><td colspan="1" rowspan="1">76 (100.0%)</td><td colspan="1" rowspan="1">1,810 (100.0%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Comorbid conditions n (%)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Hypertension</td><td colspan="1" rowspan="1">10,995 (87.2%)</td><td colspan="1" rowspan="1">6,790 (82.5%)</td><td colspan="1" rowspan="1">1,100 (96.0%)</td><td colspan="1" rowspan="1">385 (91.6%)</td><td colspan="1" rowspan="1">71 (93.3%)</td><td colspan="1" rowspan="1">1,775 (98.1%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Diabetes</td><td colspan="1" rowspan="1">3,984 (31.6%)</td><td colspan="1" rowspan="1">2,250 (27.3%)</td><td colspan="1" rowspan="1">504 (44.1%)</td><td colspan="1" rowspan="1">218 (51.8%)</td><td colspan="1" rowspan="1">20 (26.7%)</td><td colspan="1" rowspan="1">640 (35.4%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Obesity</td><td colspan="1" rowspan="1">1,625 (12.9%)</td><td colspan="1" rowspan="1">1,040 (12.6%)</td><td colspan="1" rowspan="1">177 (15.4%)</td><td colspan="1" rowspan="1">71 (16.9%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">170 (9.4%)</td><td colspan="1" rowspan="1">0.052</td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic heart failure</td><td colspan="1" rowspan="1">1,915 (15.2%)</td><td colspan="1" rowspan="1">870 (10.6%)</td><td colspan="1" rowspan="1">298 (26.0%)</td><td colspan="1" rowspan="1">127 (30.1%)</td><td colspan="1" rowspan="1">15 (20.0%)</td><td colspan="1" rowspan="1">415 (22.9%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Valvular heart disease</td><td colspan="1" rowspan="1">555 (4.4%)</td><td colspan="1" rowspan="1">272 (3.3%)</td><td colspan="1" rowspan="1">81 (7.1%)</td><td colspan="1" rowspan="1">30 (7.2%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">116 (6.4%)</td><td colspan="1" rowspan="1">0.011</td></tr><tr><td colspan="1" rowspan="1">&#160;Atrial fibrillation</td><td colspan="1" rowspan="1">1,116 (8.9%)</td><td colspan="1" rowspan="1">630 (7.7%)</td><td colspan="1" rowspan="1">156 (13.7%)</td><td colspan="1" rowspan="1">56 (13.3%)</td><td colspan="1" rowspan="1">10 (13.3%)</td><td colspan="1" rowspan="1">170 (9.4%)</td><td colspan="1" rowspan="1">0.04</td></tr><tr><td colspan="1" rowspan="1">&#160;Coronary artery disease</td><td colspan="1" rowspan="1">1,905 (15.1%)</td><td colspan="1" rowspan="1">1,120 (13.6%)</td><td colspan="1" rowspan="1">272 (23.8%)</td><td colspan="1" rowspan="1">86 (20.5%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">245 (13.5%)</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic pulmonary disease</td><td colspan="1" rowspan="1">3,066 (24.3%)</td><td colspan="1" rowspan="1">2,060 (25.0%)</td><td colspan="1" rowspan="1">308 (26.9%)</td><td colspan="1" rowspan="1">76 (18.1%)</td><td colspan="1" rowspan="1">10 (13.3%)</td><td colspan="1" rowspan="1">315 (17.4%)</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Chronic liver disease</td><td colspan="1" rowspan="1">725 (5.8%)</td><td colspan="1" rowspan="1">460 (5.6%)</td><td colspan="1" rowspan="1">40 3.5%</td><td colspan="1" rowspan="1">35 (8.4%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">100 (5.5%)</td><td colspan="1" rowspan="1">0.20</td></tr><tr><td colspan="1" rowspan="1">&#160;Metastasis cancer</td><td colspan="1" rowspan="1">610 (4.8%)</td><td colspan="1" rowspan="1">450 (5.5%)</td><td colspan="1" rowspan="1">56 (4.9%)</td><td colspan="1" rowspan="1">25 (6.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">20 (1.1%)</td><td colspan="1" rowspan="1">0.01</td></tr><tr><td colspan="1" rowspan="1">&#160;Solid tumor without metastasis</td><td colspan="1" rowspan="1">885 (7.0%)</td><td colspan="1" rowspan="1">705 (8.6%)</td><td colspan="1" rowspan="1">71 (6.2%)</td><td colspan="1" rowspan="1">15 (3.6%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">30 (1.7%)</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Solid organ transplant</td><td colspan="1" rowspan="1">379 (3.0%)</td><td colspan="1" rowspan="1">105 (1.3%)</td><td colspan="1" rowspan="1">35 (3.1%)</td><td colspan="1" rowspan="1">30 (7.2%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">100 (5.5%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Dementia</td><td colspan="1" rowspan="1">445 (3.5%)</td><td colspan="1" rowspan="1">305 (3.7%)</td><td colspan="1" rowspan="1">50 (4.4%)</td><td colspan="1" rowspan="1">15 (3.6%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">45 (2.5%)</td><td colspan="1" rowspan="1">0.79</td></tr><tr><td colspan="1" rowspan="1">&#160;history of stroke and TIA</td><td colspan="1" rowspan="1">1,070 (8.5%)</td><td colspan="1" rowspan="1">615 (7.5%)</td><td colspan="1" rowspan="1">156 (13.7%)</td><td colspan="1" rowspan="1">25 (6.0%)</td><td colspan="1" rowspan="1">10 (13.3%)</td><td colspan="1" rowspan="1">195 (10.8%)</td><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">&#160;Carotid artery stenosis</td><td colspan="1" rowspan="1">410 (3.3%)</td><td colspan="1" rowspan="1">275 (3.3%)</td><td colspan="1" rowspan="1">66 (5.7%)</td><td colspan="1" rowspan="1">10 (2.4%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">45 (2.5%)</td><td colspan="1" rowspan="1">0.18</td></tr><tr><td colspan="1" rowspan="1">&#160;Cerebral atherosclerosis</td><td colspan="1" rowspan="1">76 (0.6%)</td><td colspan="1" rowspan="1">55 (0.7%)</td><td colspan="1" rowspan="1">5 (0.4%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">5 (0.3%)</td><td colspan="1" rowspan="1">0.82</td></tr><tr><td colspan="1" rowspan="1">&#160;Migraine</td><td colspan="1" rowspan="1">900 (7.1%)</td><td colspan="1" rowspan="1">700 (8.5%)</td><td colspan="1" rowspan="1">35 (3.1%)</td><td colspan="1" rowspan="1">20 (4.8%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">105 (5.8%)</td><td colspan="1" rowspan="1">0.006</td></tr><tr><td colspan="1" rowspan="1">&#160;Rheumatologic disease<xref rid="tbl1fnb" ref-type="table-fn">b</xref></td><td colspan="1" rowspan="1">961 (7.6%)</td><td colspan="1" rowspan="1">450 (5.5%)</td><td colspan="1" rowspan="1">111 (9.7%)</td><td colspan="1" rowspan="1">51 (12.1%)</td><td colspan="1" rowspan="1">25 (33.3%)</td><td colspan="1" rowspan="1">220 (12.2%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Alcohol use disorder</td><td colspan="1" rowspan="1">905 (7.2%)</td><td colspan="1" rowspan="1">765 (9.3%)</td><td colspan="1" rowspan="1">50 (4.4%)</td><td colspan="1" rowspan="1">20 (4.8%)</td><td colspan="1" rowspan="1">10 (13.3%)</td><td colspan="1" rowspan="1">15 (0.8%)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Smoking</td><td colspan="1" rowspan="1">2,520 (20.0%)</td><td colspan="1" rowspan="1">1,650 (20.0%)</td><td colspan="1" rowspan="1">293 (25.6%)</td><td colspan="1" rowspan="1">81 (19.3%)</td><td colspan="1" rowspan="1">5 (6.7%)</td><td colspan="1" rowspan="1">305 (16.9%)</td><td colspan="1" rowspan="1">0.14</td></tr><tr><td colspan="1" rowspan="1">Drug abuse</td><td colspan="1" rowspan="1">2,160 (17.1%)</td><td colspan="1" rowspan="1">1,615 (19.6%)</td><td colspan="1" rowspan="1">151 (13.2%)</td><td colspan="1" rowspan="1">66 (15.7%)</td><td colspan="1" rowspan="1">10 (13.3%)</td><td colspan="1" rowspan="1">195 (10.8%)</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Preeclampsia and eclampsia</td><td colspan="1" rowspan="1">20 (0.2%)</td><td colspan="1" rowspan="1">20 (0.2%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1">0 (0.0%)</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: CKD, chronic kidney disease; KF, kidney failure (end-stage kidney disease); NKD, no kidney disease; PRES, posterior reversible encephalopathy syndrome; TIA, transient ischemic attack.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0015">Regions of hospital in NIS: please refer to <xref rid="appsec1" ref-type="sec">Table S2</xref>.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0020">Rheumatologic disease: rheumatologic diseases included in this study are detailed in <xref rid="appsec1" ref-type="sec">Table S1</xref>.</p></fn></table-wrap-foot></table-wrap></p><p id="p0085">The cohort exhibited a significant chronic disease burden, with 60.8% of patients having a CCI score of 3 or higher. Hypertension was the most common comorbid condition, affecting 87.2% of patients. Drug abuse was present in 17.1% of cases, 3% of patients had a history of solid organ transplantation, and 7.6% had rheumatologic diseases.</p><p id="p0090">Significant differences in patient and hospital characteristics were observed across groups (<xref rid="tbl1" ref-type="table">Table 1</xref>). Patients with KF were notably younger at the time of PRES diagnosis, with a mean age of 46.8 years, compared with 59 years in the NKD group. Furthermore, all patients with CKD stages 3-5 and KF had a CCI score of 3 or higher, compared with 40% of patients with NKD, reflecting a markedly higher comorbid condition burden. Patients with kidney disease were also more likely to be Black and from lower-income brackets compared with those without kidney disease.</p><p id="p0095"><xref rid="fig2" ref-type="fig">Fig 2</xref> illustrates the prevalence of chronic comorbid conditions across kidney disease stages. Patients with CKD had higher rates of hypertension, diabetes, chronic heart failure, valvular heart disease, atrial fibrillation, history of solid organ transplantation, and rheumatologic diseases compared with those without kidney disease. Notably, preeclampsia or eclampsia cases were absent among patients with CKD stages 3-5 and KF.<fig id="fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Rate of comorbid conditions among patients admitted for PRES with different CKD stages. PRES, posterior reversible encephalopathy syndrome; NKD, no pre-existing kidney disease; CKD, chronic kidney disease; KF, kidney failure (end-stage kidney disease).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p></sec></sec><sec id="sec3"><title>Outcomes</title><sec id="sec3.1"><title>In-Hospital All-Cause Mortality</title><p id="p0100">The overall in-hospital all-cause mortality rate among nonelectively admitted adult patients with PRES was 2.3%. Mortality rates varied significantly across groups, with 1.5% in the NKD group, 2.2% in CKD stage 3, 3.6% in CKD stage 4, 13.3% in CKD stage 5, and 5.5% in the KF group (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001) (<xref rid="tbl2" ref-type="table">Table 2</xref>). Because of a Variance Inflation Factor greater than 5, hospital teaching status was excluded from the multivariable analyses. After adjusting for confounding factors, KF was identified as an independent risk factor for increased mortality, with an adjusted odds ratio (aOR) of 5.12 (95% CI, 2.09-12.5, <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001) compared with NKD (<xref rid="tbl3" ref-type="table">Table 3</xref>). Additional independent risk factors for in-hospital mortality identified in Model 4 included chronic liver disease (aOR 3.8, 95% CI, 1.56-9.04, <italic toggle="yes">P</italic>&#160;=&#160;0.003) and metastatic cancer (aOR 8.1, 95% CI, 2.76-23.78, <italic toggle="yes">P</italic>&#160;&lt;&#160;0.001) (<xref rid="fig3" ref-type="fig">Fig 3</xref>).<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Outcomes of Adult Patients Hospitalized for PRES Stratified by CKD Stages</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="2" rowspan="1">Total<break/>N&#160;=&#160;12,605</th><th colspan="2" rowspan="1">NRD<break/>n&#160;=&#160;8,235</th><th colspan="2" rowspan="1">CKD 3<break/>n&#160;=&#160;1,145</th><th colspan="2" rowspan="1">CKD 4<break/>n&#160;=&#160;420</th><th colspan="2" rowspan="1">CKD 5<break/>n&#160;=&#160;75</th><th colspan="2" rowspan="1">KF<break/>n&#160;=&#160;1,810</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All-cause in-hospital mortality N %</td><td colspan="1" rowspan="1">285</td><td colspan="1" rowspan="1">2.3%</td><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">1.5%</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">2.2%</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">3.6%</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">13.3%</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5.5%</td><td colspan="1" rowspan="1"><bold>&lt;</bold>&#160;<bold>0.001</bold></td></tr><tr><td colspan="1" rowspan="1">ICH n %</td><td colspan="1" rowspan="1">565</td><td colspan="1" rowspan="1">4.5%</td><td colspan="1" rowspan="1">375</td><td colspan="1" rowspan="1">4.6%</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">3.1%</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">3.6%</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">13.3%</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">5.8%</td><td colspan="1" rowspan="1">0.23</td></tr><tr><td colspan="1" rowspan="1">Ischemic stroke n %</td><td colspan="1" rowspan="1">689</td><td colspan="1" rowspan="1">5.5%</td><td colspan="1" rowspan="1">425</td><td colspan="1" rowspan="1">5.2%</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">7.1%</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">9.6%</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">13.3%</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">5.0%</td><td colspan="1" rowspan="1">0.28</td></tr><tr><td colspan="1" rowspan="1">Brain herniation n %</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">70</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0.4%</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2.4%</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">6.7%</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">Status epilepticus n %</td><td colspan="1" rowspan="1">860</td><td colspan="1" rowspan="1">6.8%</td><td colspan="1" rowspan="1">545</td><td colspan="1" rowspan="1">6.6%</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">8.8%</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">14.5%</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">6.6%</td><td colspan="1" rowspan="1"><bold>0.02</bold></td></tr><tr><td colspan="1" rowspan="1">Mean LOS (d)</td><td colspan="2" rowspan="1">7.9</td><td colspan="2" rowspan="1">7.4</td><td colspan="2" rowspan="1">8.3</td><td colspan="2" rowspan="1">10.4</td><td colspan="2" rowspan="1">10.4</td><td colspan="2" rowspan="1">9.4</td><td colspan="1" rowspan="1"><bold>0.005</bold></td></tr><tr><td colspan="1" rowspan="1">Mean total hospitalization charges (USD)</td><td colspan="2" rowspan="1">91,841</td><td colspan="2" rowspan="1">85,350</td><td colspan="2" rowspan="1">91,889</td><td colspan="2" rowspan="1">144,105</td><td colspan="2" rowspan="1">118,944</td><td colspan="2" rowspan="1">111,692</td><td colspan="1" rowspan="1"><bold>0.01</bold></td></tr></tbody></table><table-wrap-foot><fn id="tspara0025"><p><italic toggle="yes">Note:</italic> Bolded values represent statistical significance.</p></fn><fn id="tspara0030"><p>Abbreviations: CKD, chronic kidney disease; ICH, intracranial hemorrhage; KF, kidney failure (end-stage kidney disease); LOS, length of stay; NKD, no kidney disease; PRES, posterior reversible encephalopathy syndrome; THC, total hospitalization charges.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="portrait"><label>Table 3</label><caption><p>Association Between Outcomes and CKD</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1"/><th colspan="3" rowspan="1">CKD Stage 3<hr/></th><th colspan="3" rowspan="1">CKD Stage 4<hr/></th><th colspan="3" rowspan="1">CKD Stage 5<hr/></th><th colspan="3" rowspan="1">KF<hr/></th></tr><tr><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="13" rowspan="1">Mortality</td></tr><tr><td colspan="1" rowspan="1">Model1:</td><td colspan="1" rowspan="1">1.46</td><td colspan="1" rowspan="1">0.56-3.85</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">2.43</td><td colspan="1" rowspan="1">0.72-8.28</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1"><bold>9.98</bold></td><td colspan="1" rowspan="1"><bold>2.25-44.4</bold></td><td colspan="1" rowspan="1"><bold>0.003</bold></td><td colspan="1" rowspan="1"><bold>3.81</bold></td><td colspan="1" rowspan="1"><bold>2.09-6.93</bold></td><td colspan="1" rowspan="1"><bold>&lt;</bold>&#160;<bold>0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">1.01</td><td colspan="1" rowspan="1">0.35-2.93</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">2.19</td><td colspan="1" rowspan="1">0.62-7.75</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1">4.85</td><td colspan="1" rowspan="1">0.56-41.8</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1"><bold>4.8</bold></td><td colspan="1" rowspan="1"><bold>2.51-9.19</bold></td><td colspan="1" rowspan="1"><bold>&lt;</bold>&#160;<bold>0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">0.92</td><td colspan="1" rowspan="1">0.31-2.74</td><td colspan="1" rowspan="1">0.88</td><td colspan="1" rowspan="1">1.32</td><td colspan="1" rowspan="1">0.29-5.98</td><td colspan="1" rowspan="1">0.72</td><td colspan="1" rowspan="1">4.63</td><td colspan="1" rowspan="1">0.52-41.4</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1"><bold>4.67</bold></td><td colspan="1" rowspan="1"><bold>2.34-9.32</bold></td><td colspan="1" rowspan="1"><bold>&lt;</bold>&#160;<bold>0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">0.32-3.67</td><td colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">0.58-8.41</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">6.69</td><td colspan="1" rowspan="1">0.65-68.8</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1"><bold>5.12</bold></td><td colspan="1" rowspan="1"><bold>2.09-12.53</bold></td><td colspan="1" rowspan="1"><bold>&lt;</bold>&#160;<bold>0.001</bold></td></tr><tr><td colspan="13" rowspan="1">ICH</td></tr><tr><td colspan="1" rowspan="1">Model 1:</td><td colspan="1" rowspan="1">0.67</td><td colspan="1" rowspan="1">0.30-1.47</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">0.79</td><td colspan="1" rowspan="1">0.24-2.56</td><td colspan="1" rowspan="1">0.69</td><td colspan="1" rowspan="1">3.22</td><td colspan="1" rowspan="1">0.72-14.36</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">1.29</td><td colspan="1" rowspan="1">0.79-2.11</td><td colspan="1" rowspan="1">0.31</td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">0.57</td><td colspan="1" rowspan="1">0.24-1.36</td><td colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.21-2.32</td><td colspan="1" rowspan="1">0.56</td><td colspan="1" rowspan="1">2.58</td><td colspan="1" rowspan="1">0.51-13/13</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">0.57-1.67</td><td colspan="1" rowspan="1">0.94</td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">0.55</td><td colspan="1" rowspan="1">0.23-1.30</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.21-2.39</td><td colspan="1" rowspan="1">0.57</td><td colspan="1" rowspan="1">2.43</td><td colspan="1" rowspan="1">0.50-11.8</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">1.01</td><td colspan="1" rowspan="1">0.37-1.78</td><td colspan="1" rowspan="1">0.98</td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">0.60</td><td colspan="1" rowspan="1">0.25-1.42</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.76</td><td colspan="1" rowspan="1">0.23-2.54</td><td colspan="1" rowspan="1">0.66</td><td colspan="1" rowspan="1">2.33</td><td colspan="1" rowspan="1">0.45-11.96</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">1.01</td><td colspan="1" rowspan="1">0.58-1.73</td><td colspan="1" rowspan="1">0.98</td></tr><tr><td colspan="13" rowspan="1">Ischemic stroke</td></tr><tr><td colspan="1" rowspan="1">Model 1:</td><td colspan="1" rowspan="1">1.39</td><td colspan="1" rowspan="1">0.80-2.43</td><td colspan="1" rowspan="1">0.24</td><td colspan="1" rowspan="1">1.96</td><td colspan="1" rowspan="1">0.91-4.20</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">2.83</td><td colspan="1" rowspan="1">0.62-12.81</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.96</td><td colspan="1" rowspan="1">0.57-1.63</td><td colspan="1" rowspan="1">0.88</td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">0.59-1.94</td><td colspan="1" rowspan="1">0.81</td><td colspan="1" rowspan="1">1.93</td><td colspan="1" rowspan="1">0.88-4.24</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">4.03</td><td colspan="1" rowspan="1">0.94-17.38</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">1.12</td><td colspan="1" rowspan="1">0.64-1.96</td><td colspan="1" rowspan="1">0.69</td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">1.07</td><td colspan="1" rowspan="1">0.59-1.95</td><td colspan="1" rowspan="1">0.81</td><td colspan="1" rowspan="1">1.92</td><td colspan="1" rowspan="1">0.87-4.23</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">3.45</td><td colspan="1" rowspan="1">0.80-14.90</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">1.11</td><td colspan="1" rowspan="1">0.61-2.02</td><td colspan="1" rowspan="1">0.74</td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">1.03</td><td colspan="1" rowspan="1">0.54-1.95</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">1.84</td><td colspan="1" rowspan="1">0.80-4.23</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">3.24</td><td colspan="1" rowspan="1">0.78-13.5</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.96</td><td colspan="1" rowspan="1">0.49-1.86</td><td colspan="1" rowspan="1">0.90</td></tr><tr><td colspan="13" rowspan="1">Brain herniation</td></tr><tr><td colspan="1" rowspan="1">Model 1:</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">0.07-3.93</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">2.89</td><td colspan="1" rowspan="1">0.64-12.9</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1"><bold>8.3</bold></td><td colspan="1" rowspan="1"><bold>1.03-67.7</bold></td><td colspan="1" rowspan="1"><bold>0.047</bold></td><td colspan="1" rowspan="1">0.97</td><td colspan="1" rowspan="1">0.28-3.43</td><td colspan="1" rowspan="1">0.97</td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">0.07-4.05</td><td colspan="1" rowspan="1">0.53</td><td colspan="1" rowspan="1">2.54</td><td colspan="1" rowspan="1">0.54-11.93</td><td colspan="1" rowspan="1">0.24</td><td colspan="1" rowspan="1">7.28</td><td colspan="1" rowspan="1">0.95-55.80</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.18-2.66</td><td colspan="1" rowspan="1">0.60</td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">0.49</td><td colspan="1" rowspan="1">0.63-3.86</td><td colspan="1" rowspan="1">0.499</td><td colspan="1" rowspan="1">2.67</td><td colspan="1" rowspan="1">0.54-13.2</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">5.83</td><td colspan="1" rowspan="1">0.69-48.88</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.22-3.67</td><td colspan="1" rowspan="1">0.88</td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">0.47</td><td colspan="1" rowspan="1">0.60-3.63</td><td colspan="1" rowspan="1">0.47</td><td colspan="1" rowspan="1">2.44</td><td colspan="1" rowspan="1">0.52-11.40</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">5.31</td><td colspan="1" rowspan="1">0.68-41.8</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.68</td><td colspan="1" rowspan="1">0.18-2.59</td><td colspan="1" rowspan="1">0.58</td></tr><tr><td colspan="13" rowspan="1">Status epilepticus</td></tr><tr><td colspan="1" rowspan="1">Model 1:</td><td colspan="1" rowspan="1">1.36</td><td colspan="1" rowspan="1">0.83-2.24</td><td colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1"><bold>2.38</bold></td><td colspan="1" rowspan="1"><bold>1.25-4.53</bold></td><td colspan="1" rowspan="1"><bold>0.008</bold></td><td colspan="1" rowspan="1">Empty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0.64-1.56</td><td colspan="1" rowspan="1">0.99</td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">1.44</td><td colspan="1" rowspan="1">0.87-2.38</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1"><bold>2.2</bold></td><td colspan="1" rowspan="1"><bold>1.10-4.42</bold></td><td colspan="1" rowspan="1"><bold>0.03</bold></td><td colspan="1" rowspan="1">Empty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.54-1.50</td><td colspan="1" rowspan="1">0.69</td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">1.45</td><td colspan="1" rowspan="1">0.87-2.44</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1"><bold>2.23</bold></td><td colspan="1" rowspan="1"><bold>1.09-4.53</bold></td><td colspan="1" rowspan="1"><bold>0.03</bold></td><td colspan="1" rowspan="1">Empty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.89</td><td colspan="1" rowspan="1">0.52-1.55</td><td colspan="1" rowspan="1">0.69</td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">1.24</td><td colspan="1" rowspan="1">0.72-2.16</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1"><bold>2.03</bold></td><td colspan="1" rowspan="1"><bold>1.03-4.01</bold></td><td colspan="1" rowspan="1"><bold>0.04</bold></td><td colspan="1" rowspan="1">Empty</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">0.54-1.49</td><td colspan="1" rowspan="1">0.68</td></tr><tr><td colspan="13" rowspan="1">LOS</td></tr><tr><td colspan="1" rowspan="1">Model 1:</td><td colspan="1" rowspan="1">0.91</td><td colspan="1" rowspan="1">&#8722;0.09 to 1.9</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1"><bold>3.1</bold></td><td colspan="1" rowspan="1"><bold>0.70-5.49</bold></td><td colspan="1" rowspan="1"><bold>0.01</bold></td><td colspan="1" rowspan="1">3.05</td><td colspan="1" rowspan="1">&#8722;1.42 to 7.51</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1"><bold>2.04</bold></td><td colspan="1" rowspan="1"><bold>0.60-3.48</bold></td><td colspan="1" rowspan="1"><bold>0.005</bold></td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">0.62</td><td colspan="1" rowspan="1">&#8722;0.46 to 1.70</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1"><bold>2.46</bold></td><td colspan="1" rowspan="1"><bold>0.038-4.89</bold></td><td colspan="1" rowspan="1"><bold>0.047</bold></td><td colspan="1" rowspan="1">1.67</td><td colspan="1" rowspan="1">&#8722;2.21 to 5.56</td><td colspan="1" rowspan="1">0.40</td><td colspan="1" rowspan="1"><bold>2.1</bold></td><td colspan="1" rowspan="1"><bold>0.56-3.65</bold></td><td colspan="1" rowspan="1"><bold>0.008</bold></td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">0.47</td><td colspan="1" rowspan="1">&#8722;0.61 to 1.56</td><td colspan="1" rowspan="1">0.39</td><td colspan="1" rowspan="1"><bold>2.47</bold></td><td colspan="1" rowspan="1"><bold>0.02-4.91</bold></td><td colspan="1" rowspan="1"><bold>0.048</bold></td><td colspan="1" rowspan="1">0.69</td><td colspan="1" rowspan="1">&#8722;3.17 to 4.56</td><td colspan="1" rowspan="1">0.73</td><td colspan="1" rowspan="1"><bold>1.79</bold></td><td colspan="1" rowspan="1"><bold>0.15-3.42</bold></td><td colspan="1" rowspan="1"><bold>0.03</bold></td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">&#8722;0.5</td><td colspan="1" rowspan="1">&#8722;2.55</td><td colspan="1" rowspan="1">0.44</td><td colspan="1" rowspan="1">0.9</td><td colspan="1" rowspan="1">&#8722;1.52 to 3.32</td><td colspan="1" rowspan="1">0.47</td><td colspan="1" rowspan="1">&#8722;0.23</td><td colspan="1" rowspan="1">&#8722;4.08 to 3.61</td><td colspan="1" rowspan="1">0.91</td><td colspan="1" rowspan="1">0.63</td><td colspan="1" rowspan="1">&#8722;1.10 to 2.37</td><td colspan="1" rowspan="1">0.47</td></tr><tr><td colspan="13" rowspan="1">Total hospitalization charges</td></tr><tr><td colspan="1" rowspan="1">Model 1:</td><td colspan="1" rowspan="1">6,539.00</td><td colspan="1" rowspan="1">&#8722;9,066 to 22,144</td><td colspan="1" rowspan="1">0.41</td><td colspan="1" rowspan="1">58,754</td><td colspan="1" rowspan="1">&#8722;14,300 to 131,809</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">33,594</td><td colspan="1" rowspan="1">&#8722;25,224 to 92,413</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1"><bold>26,341</bold></td><td colspan="1" rowspan="1"><bold>7,566-45,117</bold></td><td colspan="1" rowspan="1"><bold>0.006</bold></td></tr><tr><td colspan="1" rowspan="1">Model 2:</td><td colspan="1" rowspan="1">5,091.00</td><td colspan="1" rowspan="1">&#8722;11,410-21,591</td><td colspan="1" rowspan="1">0.55</td><td colspan="1" rowspan="1">54,305</td><td colspan="1" rowspan="1">&#8722;18,061 to 126,671</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">2,408</td><td colspan="1" rowspan="1">&#8722;49,465 to 54,280</td><td colspan="1" rowspan="1">0.93</td><td colspan="1" rowspan="1"><bold>22,220</bold></td><td colspan="1" rowspan="1"><bold>2,862-41,579</bold></td><td colspan="1" rowspan="1"><bold>0.02</bold></td></tr><tr><td colspan="1" rowspan="1">Model 3:</td><td colspan="1" rowspan="1">3,611.00</td><td colspan="1" rowspan="1">&#8722;12,522 to 19,744</td><td colspan="1" rowspan="1">0.66</td><td colspan="1" rowspan="1">57,288</td><td colspan="1" rowspan="1">&#8722;17,849 to 132,456</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">&#8722;6,842</td><td colspan="1" rowspan="1">&#8722;58,101 to 44,417</td><td colspan="1" rowspan="1">0.79</td><td colspan="1" rowspan="1">20,347</td><td colspan="1" rowspan="1">&#8722;1,952 to 42,646</td><td colspan="1" rowspan="1">0.07</td></tr><tr><td colspan="1" rowspan="1">Model 4:</td><td colspan="1" rowspan="1">&#8722;5,889.00</td><td colspan="1" rowspan="1">&#8722;24,770 to 12,991</td><td colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1">38,814</td><td colspan="1" rowspan="1">&#8722;35,348 to 112,977</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">&#8722;18,473</td><td colspan="1" rowspan="1">&#8722;67,165 to 30,220</td><td colspan="1" rowspan="1">0.46</td><td colspan="1" rowspan="1">9,789</td><td colspan="1" rowspan="1">&#8722;14,027 to 33,606</td><td colspan="1" rowspan="1">0.42</td></tr></tbody></table><table-wrap-foot><fn id="tspara0040"><p><italic toggle="yes">Note:</italic> Bolded values represent statistical significance. Model 1: Univariate analysis; Model 2: adjusted for demographic factors; Model 3 adjusted for demographics, socioeconomic indicators, and hospital characteristics; Model 4 adjusted comorbid conditions in addition to the adjustments in Model 3 and included only variables that demonstrated an association with outcomes at a <italic toggle="yes">P</italic>&#160;&lt;&#160;0.2 in univariate analysis.</p></fn><fn id="tspara0045"><p>Abbreviations: CKD, chronic kidney disease; ICH, intracranial hemorrhage; KF, kidney failure (end-stage kidney disease); LOS, length of stay; NKD, no kidney disease.</p></fn></table-wrap-foot></table-wrap><fig id="fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Multivariate analyses (Model 4) identified risk factors for PRES in-hospital all-cause mortality. Model 4 adjusted for demographics, socioeconomic indicators, and hospital characteristics, also incorporated comorbid conditions that demonstrated an association with mortality at a <italic toggle="yes">P</italic>&#160;&lt;&#160;0.2 in univariate analysis. Statistical significance was defined as a 2-sided <italic toggle="yes">P</italic>&#160;&lt;&#160;0.05. PRES, posterior reversible encephalopathy syndrome; NKD, no pre-existing kidney disease; CKD, chronic kidney disease; KF, kidney failure (end-stage kidney disease); CCI, Charlson Comorbidity Index. Bolded values represent statistical significance.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0105">Trends in in-hospital all-cause mortality for PRES were evaluated from 2016 to 2019, adjusting for age and gender. No significant differences in mortality rates were observed over this period.</p></sec><sec id="sec3.2"><title>Incidence of PRES Hospitalizations</title><p id="p0110">From 2016 and 2019, there were 93 million nonelective hospitalizations among patients aged &gt;18 years, of which 12,605 were attributed to a principal diagnosis of PRES, yielding an overall incidence of 0.014%. Incidence rates varied by subgroup, with 0.015% for CKD stage 3, 0.020% for CKD stage 4, 0.027% for CKD stage 5, 0.048% for ESKD, and 0.011% for the NKD group. Because of a Variance Inflation Factor greater than 5, the CCI was excluded from multivariable analyses.</p><p id="p0115">In addition to the 4 primary multivariable models, a fifth model was developed that included only morbidities identified as PRES-relevant in previous literature, such as hypertension, history of solid organ transplantation, rheumatologic disorders, drug use, and malignancy.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Across all 5 statistical models, a dose-dependent relationship was consistently observed, with the likelihood of PRES hospitalizations increasing with advancing CKD stage (<xref rid="tbl4" ref-type="table">Table 4</xref>). Model 4 also identified several additional independent risk factors for PRES hospitalizations, such as female sex, White race, hypertension, metastatic cancer, history of solid organ transplantation, rheumatologic disorders, drug abuse, carotid artery stenosis, migraines, and cerebral atherosclerosis (<xref rid="tbl5" ref-type="table">Table 5</xref>).<table-wrap position="float" id="tbl4" orientation="portrait"><label>Table 4</label><caption><p>Association Between PRES Hospitalizations and CKD</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">PRES hospitalizations</th><th colspan="3" rowspan="1">CKD 3<hr/></th><th colspan="3" rowspan="1">CKD 4<hr/></th><th colspan="3" rowspan="1">CKD 5<hr/></th><th colspan="3" rowspan="1">KF<hr/></th></tr><tr><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Model 1</td><td colspan="1" rowspan="1"><bold>1.40</bold></td><td colspan="1" rowspan="1"><bold>1.21-1.61</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.81</bold></td><td colspan="1" rowspan="1"><bold>1.46-2.24</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.44</bold></td><td colspan="1" rowspan="1"><bold>1.47-4.04</bold></td><td colspan="1" rowspan="1"><bold>0.001</bold></td><td colspan="1" rowspan="1"><bold>4.38</bold></td><td colspan="1" rowspan="1"><bold>3.91-4.91</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 2</td><td colspan="1" rowspan="1"><bold>1.79</bold></td><td colspan="1" rowspan="1"><bold>1.53-2.08</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.29</bold></td><td colspan="1" rowspan="1"><bold>1.83-2.88</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>3.09</bold></td><td colspan="1" rowspan="1"><bold>1.82-5.24</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>5.67</bold></td><td colspan="1" rowspan="1"><bold>5.01-6.42</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 3</td><td colspan="1" rowspan="1"><bold>1.77</bold></td><td colspan="1" rowspan="1"><bold>1.52-2.07</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.3</bold></td><td colspan="1" rowspan="1"><bold>1.83-2.88</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>3.03</bold></td><td colspan="1" rowspan="1"><bold>1.79-5.14</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>5.31</bold></td><td colspan="1" rowspan="1"><bold>4.69-6.01</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 4</td><td colspan="1" rowspan="1"><bold>1.77</bold></td><td colspan="1" rowspan="1"><bold>1.52-2.07</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.45</bold></td><td colspan="1" rowspan="1"><bold>1.95-3.06</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.58</bold></td><td colspan="1" rowspan="1"><bold>1.52-4.38</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>4.09</bold></td><td colspan="1" rowspan="1"><bold>3.59-4.65</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Model 5</td><td colspan="1" rowspan="1"><bold>1.44</bold></td><td colspan="1" rowspan="1"><bold>1.24-1.66%</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.89</bold></td><td colspan="1" rowspan="1"><bold>1.51-2.35</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.17</bold></td><td colspan="1" rowspan="1"><bold>1.28-3.67</bold></td><td colspan="1" rowspan="1"><bold>0.004</bold></td><td colspan="1" rowspan="1"><bold>3.2</bold></td><td colspan="1" rowspan="1"><bold>2.84-3.60</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr></tbody></table><table-wrap-foot><fn id="tspara0055"><p><italic toggle="yes">Note:</italic> Bolded values represent statistical significance.</p></fn><fn id="tspara0060"><p>Model 1: Univariate analysis; Model 2: adjusted for demographic factors; Model 3 adjusted for demographics, socioeconomic indicators, and hospital characteristics; Model 4 adjusted comorbid conditions in addition to the adjustments in Model 3 and included only variables that demonstrated an association with outcomes at a <italic toggle="yes">p</italic> &lt;0.2 in univariate analysis; Model 5 adjusted for comorbid conditions identified as PRES-relevant in addition to the adjustments in Model 3.</p></fn><fn id="tspara0065"><p>Abbreviations: CKD, chronic kidney disease; KF, kidney failure (end-stage kidney disease); PRES, posterior reversible encephalopathy syndrome.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl5" orientation="portrait"><label>Table 5</label><caption><p>Risk Factors for Increased Incidence of PRES Hospitalizations</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">Variables</th><th colspan="3" rowspan="1">Univariate Regression Model Model 1<hr/></th><th colspan="3" rowspan="1">Multivariable Regression Model 4<hr/></th></tr><tr><th colspan="1" rowspan="1">OR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th colspan="1" rowspan="1">aOR</th><th colspan="1" rowspan="1">95% CI</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CKD status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">NCKD as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;CKD stage 3</td><td colspan="1" rowspan="1"><bold>1.40</bold></td><td colspan="1" rowspan="1"><bold>1.21-1.61</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.77</bold></td><td colspan="1" rowspan="1"><bold>1.52-2.07</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;CKD stage 4</td><td colspan="1" rowspan="1"><bold>1.81</bold></td><td colspan="1" rowspan="1"><bold>1.46-2.24</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.45</bold></td><td colspan="1" rowspan="1"><bold>1.95-3.06</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;CKD stage 5</td><td colspan="1" rowspan="1"><bold>2.44</bold></td><td colspan="1" rowspan="1"><bold>1.47-4.04</bold></td><td colspan="1" rowspan="1"><bold>0.001</bold></td><td colspan="1" rowspan="1"><bold>2.58</bold></td><td colspan="1" rowspan="1"><bold>1.52-4.38</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;KF</td><td colspan="1" rowspan="1"><bold>4.38</bold></td><td colspan="1" rowspan="1"><bold>3.91-4.91</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>4.09</bold></td><td colspan="1" rowspan="1"><bold>3.59-4.65</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1"><bold>0.99</bold></td><td colspan="1" rowspan="1"><bold>0.99-0.99</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.98</bold></td><td colspan="1" rowspan="1"><bold>0.97-0.98</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1"><bold>2.06</bold></td><td colspan="1" rowspan="1"><bold>1.89-2.25</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.45</bold></td><td colspan="1" rowspan="1"><bold>2.23-2.69</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Race</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">White as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Black</td><td colspan="1" rowspan="1">0.99</td><td colspan="1" rowspan="1">0.89-1.11</td><td colspan="1" rowspan="1">0.92</td><td colspan="1" rowspan="1"><bold>0.55</bold></td><td colspan="1" rowspan="1"><bold>0.49-0.62</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Hispanic</td><td colspan="1" rowspan="1"><bold>0.47</bold></td><td colspan="1" rowspan="1"><bold>0.40-0.56</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.38</bold></td><td colspan="1" rowspan="1"><bold>0.32-0.46</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Asian or Pacific Islander</td><td colspan="1" rowspan="1"><bold>0.39</bold></td><td colspan="1" rowspan="1"><bold>0.27-0.56</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.33</bold></td><td colspan="1" rowspan="1"><bold>0.23-0.49</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Native American</td><td colspan="1" rowspan="1"><bold>0.52</bold></td><td colspan="1" rowspan="1"><bold>0.27-0.99</bold></td><td colspan="1" rowspan="1"><bold>0.049</bold></td><td colspan="1" rowspan="1"><bold>0.41</bold></td><td colspan="1" rowspan="1"><bold>0.21-0.78</bold></td><td colspan="1" rowspan="1"><bold>0.007</bold></td></tr><tr><td colspan="2" rowspan="1">Median household income</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">$1-$49,999 as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;$50,000-$64,999</td><td colspan="1" rowspan="1">1.03</td><td colspan="1" rowspan="1">0.93-1.15</td><td colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1">1.08</td><td colspan="1" rowspan="1">0.96-1.20</td><td colspan="1" rowspan="1">0.20</td></tr><tr><td colspan="1" rowspan="1">&#160;$65,000-$85,999</td><td colspan="1" rowspan="1">1.09</td><td colspan="1" rowspan="1">0.97-1.21</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">1.12</td><td colspan="1" rowspan="1">1.00-1.26</td><td colspan="1" rowspan="1">0.06</td></tr><tr><td colspan="1" rowspan="1">&#160;$86,000 or more</td><td colspan="1" rowspan="1">0.85</td><td colspan="1" rowspan="1">0.75-0.96</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">0.96</td><td colspan="1" rowspan="1">0.84-1.10</td><td colspan="1" rowspan="1">0.58</td></tr><tr><td colspan="1" rowspan="1">Insurance status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="3" rowspan="5">not included</td></tr><tr><td colspan="1" rowspan="1">Medicare as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medicaid</td><td colspan="1" rowspan="1">1.02</td><td colspan="1" rowspan="1">0.92-1.14</td><td colspan="1" rowspan="1">0.66</td></tr><tr><td colspan="1" rowspan="1">&#160;Private including HMO</td><td colspan="1" rowspan="1">1.01</td><td colspan="1" rowspan="1">0.91-1.12</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">&#160;Self-pay</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.77-1.14</td><td colspan="1" rowspan="1">0.54</td></tr><tr><td colspan="1" rowspan="1">Hospital bed size</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Small as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medium</td><td colspan="1" rowspan="1"><bold>1.47</bold></td><td colspan="1" rowspan="1"><bold>1.27-1.71</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.48</bold></td><td colspan="1" rowspan="1"><bold>1.27-1.72</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Large</td><td colspan="1" rowspan="1"><bold>2.40</bold></td><td colspan="1" rowspan="1"><bold>2.10-2.75</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.48</bold></td><td colspan="1" rowspan="1"><bold>2.16-2.85</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="3" rowspan="1">Hospital location/teaching status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Rural as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Urban nonteaching</td><td colspan="1" rowspan="1"><bold>1.76</bold></td><td colspan="1" rowspan="1"><bold>1.38-2.26</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.86</bold></td><td colspan="1" rowspan="1"><bold>1.44-2.40</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;Urban teaching</td><td colspan="1" rowspan="1"><bold>3.11</bold></td><td colspan="1" rowspan="1"><bold>2.47-3.91</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>3.46</bold></td><td colspan="1" rowspan="1"><bold>2.72-4.40</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Hospital region</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Northeast as reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Midwest</td><td colspan="1" rowspan="1">1.13</td><td colspan="1" rowspan="1">0.98-1.30</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0.87-1.15</td><td colspan="1" rowspan="1">0.97</td></tr><tr><td colspan="1" rowspan="1">&#160;South</td><td colspan="1" rowspan="1"><bold>1.21</bold></td><td colspan="1" rowspan="1"><bold>1.06-1.38</bold></td><td colspan="1" rowspan="1"><bold>0.004</bold></td><td colspan="1" rowspan="1"><bold>1.18</bold></td><td colspan="1" rowspan="1"><bold>1.04-1.35</bold></td><td colspan="1" rowspan="1"><bold>0.01</bold></td></tr><tr><td colspan="1" rowspan="1">&#160;West</td><td colspan="1" rowspan="1">1.05</td><td colspan="1" rowspan="1">0.91-1.21</td><td colspan="1" rowspan="1">0.51</td><td colspan="1" rowspan="1">1.04</td><td colspan="1" rowspan="1">0.90-1.20</td><td colspan="1" rowspan="1">0.60</td></tr><tr><td colspan="1" rowspan="1">Hypertension</td><td colspan="1" rowspan="1"><bold>5.54</bold></td><td colspan="1" rowspan="1"><bold>4.92-6.24</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>10.07</bold></td><td colspan="1" rowspan="1"><bold>8.56-11.8</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1"><bold>1.14</bold></td><td colspan="1" rowspan="1"><bold>1.05-1.24</bold></td><td colspan="1" rowspan="1"><bold>0.002</bold></td><td colspan="1" rowspan="1"><bold>0.87</bold></td><td colspan="1" rowspan="1"><bold>0.79-0.96</bold></td><td colspan="1" rowspan="1"><bold>0.005</bold></td></tr><tr><td colspan="1" rowspan="1">Obesity</td><td colspan="1" rowspan="1"><bold>0.82</bold></td><td colspan="1" rowspan="1"><bold>0.73-0.92</bold></td><td colspan="1" rowspan="1"><bold>0.001</bold></td><td colspan="1" rowspan="1"><bold>0.61</bold></td><td colspan="1" rowspan="1"><bold>0.53-0.69</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Chronic heart failure</td><td colspan="1" rowspan="1"><bold>0.65</bold></td><td colspan="1" rowspan="1"><bold>0.58-0.72</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.68</bold></td><td colspan="1" rowspan="1"><bold>0.60-0.78</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Valve disease</td><td colspan="1" rowspan="1"><bold>0.58</bold></td><td colspan="1" rowspan="1"><bold>0.48-0.70</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.67</bold></td><td colspan="1" rowspan="1"><bold>0.54-0.83</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Atrial fibrillation</td><td colspan="1" rowspan="1"><bold>0.51</bold></td><td colspan="1" rowspan="1"><bold>0.44-0.59</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.63</bold></td><td colspan="1" rowspan="1"><bold>0.54-0.74</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Coronary artery disease</td><td colspan="1" rowspan="1"><bold>0.63</bold></td><td colspan="1" rowspan="1"><bold>0.56-0.70</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>0.63</bold></td><td colspan="1" rowspan="1"><bold>0.56-0.72</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Chronic pulmonary disease</td><td colspan="1" rowspan="1">0.97</td><td colspan="1" rowspan="1">0.9-1.06</td><td colspan="1" rowspan="1">0.47</td><td colspan="3" rowspan="1">Not included</td></tr><tr><td colspan="1" rowspan="1">Chronic liver disease</td><td colspan="1" rowspan="1">0.87</td><td colspan="1" rowspan="1">0.73-1.02</td><td colspan="1" rowspan="1">0.090</td><td colspan="1" rowspan="1"><bold>0.71</bold></td><td colspan="1" rowspan="1"><bold>0.60-0.84</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Metastasis cancer</td><td colspan="1" rowspan="1"><bold>1.39</bold></td><td colspan="1" rowspan="1"><bold>1.16-1.67</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.35</bold></td><td colspan="1" rowspan="1"><bold>1.07-1.71</bold></td><td colspan="1" rowspan="1"><bold>0.01</bold></td></tr><tr><td colspan="1" rowspan="1">Solid tumor without metastasis</td><td colspan="1" rowspan="1"><bold>1.22</bold></td><td colspan="1" rowspan="1"><bold>1.05-1.41</bold></td><td colspan="1" rowspan="1"><bold>0.01</bold></td><td colspan="1" rowspan="1">1.15</td><td colspan="1" rowspan="1">0.95-1.40</td><td colspan="1" rowspan="1">0.15</td></tr><tr><td colspan="1" rowspan="1">Solid organ transplant</td><td colspan="1" rowspan="1"><bold>4.54</bold></td><td colspan="1" rowspan="1"><bold>3.62-5.71</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.74</bold></td><td colspan="1" rowspan="1"><bold>1.35-2.25</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Dementia</td><td colspan="1" rowspan="1"><bold>0.70</bold></td><td colspan="1" rowspan="1"><bold>0.56-0.86</bold></td><td colspan="1" rowspan="1"><bold>0.001</bold></td><td colspan="1" rowspan="1">0.89</td><td colspan="1" rowspan="1">0.71-1.11</td><td colspan="1" rowspan="1">0.31</td></tr><tr><td colspan="1" rowspan="1">History of stroke/TIA</td><td colspan="1" rowspan="1"><bold>1.26</bold></td><td colspan="1" rowspan="1"><bold>1.10-1.46</bold></td><td colspan="1" rowspan="1"><bold>0.001</bold></td><td colspan="1" rowspan="1">1.16</td><td colspan="1" rowspan="1">1.00-1.34</td><td colspan="1" rowspan="1">0.054</td></tr><tr><td colspan="1" rowspan="1">Carotid artery stenosis</td><td colspan="1" rowspan="1"><bold>3.02</bold></td><td colspan="1" rowspan="1"><bold>2.42-3.77</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.99</bold></td><td colspan="1" rowspan="1"><bold>2.36-3.79</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Cerebral atherosclerosis</td><td colspan="1" rowspan="1"><bold>4.58</bold></td><td colspan="1" rowspan="1"><bold>2.76-7.59</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>3.13</bold></td><td colspan="1" rowspan="1"><bold>1.85-5.29</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Migraine</td><td colspan="1" rowspan="1"><bold>4.35</bold></td><td colspan="1" rowspan="1"><bold>3.73-5.06</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.75</bold></td><td colspan="1" rowspan="1"><bold>2.34-3.22</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Rheumatologic disease</td><td colspan="1" rowspan="1"><bold>2.57</bold></td><td colspan="1" rowspan="1"><bold>2.22-2.98</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>1.72</bold></td><td colspan="1" rowspan="1"><bold>1.48-2.00</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Drug abuse</td><td colspan="1" rowspan="1"><bold>2.38</bold></td><td colspan="1" rowspan="1"><bold>2.14-2.64</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td><td colspan="1" rowspan="1"><bold>2.5</bold></td><td colspan="1" rowspan="1"><bold>2.22-2.81</bold></td><td colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td colspan="1" rowspan="1">Smoking</td><td colspan="1" rowspan="1">0.98</td><td colspan="1" rowspan="1">0.89-1.08</td><td colspan="1" rowspan="1">0.69</td><td colspan="3" rowspan="1">Not included</td></tr><tr><td colspan="1" rowspan="1">Alcohol use disorder</td><td colspan="1" rowspan="1">0.94</td><td colspan="1" rowspan="1">0.81-1.10</td><td colspan="1" rowspan="1">0.44</td><td colspan="3" rowspan="1">Not included</td></tr></tbody></table><table-wrap-foot><fn id="tspara0075"><p><italic toggle="yes">Note:</italic> Bolded values represent statistical significance.</p></fn><fn id="tspara0080"><p>Abbreviations: CKD, chronic kidney disease; NKD, no kidney disease; KF, kidney failure (end-stage kidney disease); PRES, posterior reversible encephalopathy syndrome; TIA, transient ischemic attack.</p></fn></table-wrap-foot></table-wrap></p><p id="p0120">Trends in the incidence of PRES hospitalizations were analyzed from 2016 to 2019, adjusting for age and gender. A significant increase in PRES hospitalizations was observed during this period, rising from 0.013% to 0.015% (trend <italic toggle="yes">P</italic> = 0.01).</p></sec><sec id="sec3.3"><title>Morbidity</title><p id="p0125">Intracranial hemorrhage (ICH) occurred in 4.5% of hospitalized patients with PRES, with no significant differences in incidence across CKD stages and patients with NKD (<xref rid="tbl2" ref-type="table">Tables 2</xref> and <xref rid="tbl3" ref-type="table">3</xref>). However, Black patients had significantly higher odds of ICH (aOR 1.62, 95% CI, 1.01-2.6, <italic toggle="yes">P</italic>&#160;=&#160;0.047). Ischemic stroke was observed in 5.5% of patients, similarly, showing no significant differences between CKD and NKD groups. Older age (aOR 1.02, 95% CI, 1.01-1.03, <italic toggle="yes">P</italic>&#160;=&#160;0.01) and dementia (aOR 2.04, 95% CI, 1.03-4.1, <italic toggle="yes">P</italic>&#160;=&#160;0.04) were identified as risk factors for ischemic stroke. Brain herniation occurred in 0.8% of patients, with no significant differences between CKD and NKD groups. Status epilepticus affected 6.8% of patients, with CKD stage 4 associated with higher odds (aOR 2.03, 95% CI, 1.03-4.01, <italic toggle="yes">P</italic>&#160;=&#160;0.04). Chronic liver disease was also a risk factor for status epilepticus (aOR 2.05, 95% CI, 1.18-3.55, <italic toggle="yes">P</italic> = 0.01).</p></sec><sec id="sec3.4"><title>Resource Utilization</title><p id="p0130">The overall mean LOS for hospitalized adult patients with PRES was 7.9 days, with group-specific averages of 7.4 days for NKD, 8.3 days for CKD stage 3, 10.4 days for CKD stages 4 and 5, and 9.4 days for KF (<xref rid="tbl3" ref-type="table">Table 3</xref>). Although earlier regression models (Models 1-3) suggested increased LOS for patients with CKD, adjusted analysis in Model 4 found no significant differences in LOS between CKD and NKD groups (<xref rid="tbl4" ref-type="table">Table 4</xref>). Similarly, the mean total hospitalization charge was $91,841, but adjusted analysis revealed no statistically significant differences in charges across the groups (<xref rid="tbl4" ref-type="table">Table 4</xref>).</p></sec></sec><sec id="sec4"><title>Discussion</title><p id="p0135">This study used the largest inpatient database in the United States to conduct a comprehensive analysis of adult patients hospitalized with PRES from 2016 to 2019. Including over 12,000 patients, it represents the most extensive comparative study to date on the incidence, outcomes, and resource utilization of PRES in individuals with CKD compared with those with NKD.</p><p id="p0140">The findings of this study are fourfold. First, the incidence of PRES hospitalizations was higher in patients with CKD than in the NKD group, with a clear dose-response relationship observed across advancing CKD stages. Second, KF was identified as an independent risk factor for increased in-hospital mortality. Third, no significant differences were found in the rates of ICH, ischemic stroke, brain herniation, mechanical ventilation, LOS, or total hospital charges between patients with CKD and NKD. Fourth, additional risk factors for PRES hospitalizations and in-hospital mortality were identified, enhancing our understanding of this condition.</p><p id="p0145">Nearly 2 decades after PRES was first described in a seminal case series involving 15 patients, it remains a rare condition. Determining its incidence in the general population, particularly among patients with kidney disease, has been challenging due to the reliance on small-scale studies.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> For instance, Canny reported an incidence of 0.84% among 592 cases of KF over a 10-year period, identifying 5 cases of PRES in this population.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In contrast, our study, which included 12,605 cases of PRES, reported an incidence of PRES hospitalizations among all nonelectively admitted adults at 0.014%, and 0.048% specifically for KF. These findings provide a more robust estimate of its prevalence while underscoring its rarity. Moreover, a rising trend in PRES hospitalizations was observed from 2016 to 2019, likely attributable to improved recognition and diagnosis facilitated by advances in neuroimaging technology and increased accessibility. The higher incidence of PRES in larger urban hospitals may reflect enhanced diagnostic capabilities, including greater MRI availability, and heightened awareness of the condition.</p><p id="p0150">In this cohort, 71.5% of patients were female, 72.5% were White, and the mean age was 57.5 years. These findings are consistent with previous studies showing that PRES predominantly affects women, is more common among White individuals, and typically occurs in young to middle-aged adults.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>&#160;Notably, the female predominance persisted among patients with CKD, despite the absence of eclampsia or preeclampsia cases in these subgroups, potentially reflecting a distinct etiological distribution of PRES. Multivariate analysis further indicated that both White ethnicity and female sex are independent risk factors for PRES.</p><p id="p0155">Many studies have reported a heterogeneous association between kidney diseases and PRES, with findings ranging from no significant correlation in some series to a prevalence of approximately 30% in others.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> In our study, CKD was identified as an independent risk factor for PRES hospitalizations, with a clear dose-response relationship demonstrating progressively increasing odds of developing PRES from CKD stage 3 to KF. Despite the substantial burden of CKD, the incidence of confirmed PRES cases remains low, likely due in part to underdiagnosis. Because PRES requires imaging, such as MRI, for definitive confirmation, cases may go unrecognized&#8212;particularly in patients who do not undergo imaging despite presenting with suggestive symptoms. Given its reversible nature with adequate blood pressure control, the condition may resolve before a diagnosis is made.</p><p id="p0160">The pathophysiological mechanisms underlying PRES remain unclear, but 2 primary hypotheses have been proposed: (1) cerebrovascular dysregulation and blood-brain barrier (BBB) dysfunction, leading to vasogenic edema, a hallmark of PRES.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Severe, acute hypertension may compromise BBB integrity, resulting in vasogenic edema that predominantly affects the white matter,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> with the posterior cerebral circulation being particularly vulnerable due to its relatively lower sympathetic innervation.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> (2) Endothelial dysfunction, often mediated by cytokines and triggered by toxic agents such as chemotherapeutic drugs, immunosuppressive therapies or systemic conditions like autoimmune diseases, cancer, or sepsis, which compromise vascular integrity and function.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref> In patients with CKD, the increased incidence of PRES likely reflects multifactorial contributors, such as chronic endothelial dysfunction associated with uremia, cytokine-mediated BBB damage from persistent inflammation, and cerebrovascular dysregulation caused by resistant hypertension or fluctuating blood pressures.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> The higher prevalence of fluid overload in patients with CKD may further increase the risk, consistent with the hyper-perfusion hypothesis that implicates autoregulatory failure as a key mechanism. Moreover, hemodialysis initiation may exacerbate the risk through rapid shifts in urea, acid-base status, and electrolyte levels, disrupting endothelial function and promoting vasogenic edema.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Vasoconstriction induced by erythropoietin infusion is another potential contributing factor.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Despite these insights, the precise mechanisms linking CKD to PRES remain poorly understood. Further research is needed to elucidate these pathophysiological pathways.</p><p id="p0165">In addition to well-established factors associated with PRES, such as hypertension, metastatic malignancy, history of solid organ transplantation, and rheumatologic disorders,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> our study identified several additional independent risk factors for increased PRES incidence. These newly identified factors include female sex, White race, drug abuse, carotid artery stenosis, migraines, and cerebral atherosclerosis, providing a more comprehensive understanding of PRES and its multifactorial etiology.</p><p id="p0170">Our study demonstrated significantly higher in-hospital mortality rates among patients with CKD, ranging from 2.2% to 13.3%, compared with 1.5% in the NKD group. Notably, KF was identified as an independent risk factor for in-hospital mortality, with aOR of 5.12. These findings align with a previous study by Alshami et al,<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> which reported an aOR of 7 for KF in a cohort of 635 patients.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> This consistency underscores the markedly elevated mortality risk associated with PRES in patients with KF, emphasizing the need for heightened clinical vigilance.</p><p id="p0175">The elevated mortality observed in patients with CKD likely results from several factors, primarily the significant burden of comorbid conditions in this population. In our study, all patients with CKD stage 3 or higher had a CCI score exceeding 3, underscoring their severe comorbid condition burden. These comorbid conditions independently increase mortality risk, as demonstrated by our multivariate analysis, which identified chronic liver disease (aOR 3.8) and metastatic cancer (aOR 8.1) as key predictors of mortality. Such conditions exacerbate patient frailty and complicate clinical management, further heightening the risk of mortality in this population. Interestingly, there were no significant differences in neurological complications of PRES, such as ICH, ischemic stroke, or brain herniation, between patients with CKD and NKD. This suggests that many patients with CKD may have died of non-PRES-related causes. Notably, CKD stage 4 was identified as an independent risk factor for status epilepticus, likely attributable to uremia.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> The absence of status epilepticus in CKD stage 5 patients may reflect the limited sample size in this subgroup, which restricts definitive conclusions.</p><p id="p0180">Despite the strengths of our study, including the use of a large, nationally representative sample of the US inpatient population, several limitations should be acknowledged. First, although the ICD code for PRES is considered reliable in previous literature, the potential for misclassification persists. By focusing on nonelectively hospitalized patients with PRES, we may have excluded individuals with milder cases who did not seek acute care or who were admitted electively, potentially underestimating the true incidence of PRES. Second, our data was derived from an administrative database that does not contain detailed clinical information. As a result, key variables such as blood pressure levels, hypertension severity, and medication usage, including specific immunosuppressive therapies, were unavailable. Furthermore, the identification of clinical conditions and procedures relied on hospital-reported diagnosis and procedure codes, making the database susceptible to inaccuracies and missing data. Third, the retrospective design inherently limits the ability to establish causality and may leave room for residual confounding despite adjustments for known variables. Future studies should aim to systematically investigate the long-term complications and outcomes of PRES to build on the knowledge generated by this work.</p><p id="p0185">In conclusion, our study highlights a strong association between CKD and PRES, with a clear dose-response relationship, and establishes ESKD as an independent risk factor for in-hospital mortality. These findings emphasize the importance of heightened clinical vigilance for this high-risk population.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>Hinchey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>C.</given-names></name><name name-style="western"><surname>Appignani</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A reversible posterior leukoencephalopathy syndrome</article-title><source>N Engl J Med</source><volume>334</volume><issue>8</issue><year>1996</year><fpage>494</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1056/NEJM199602223340803</pub-id><pub-id pub-id-type="pmid">8559202</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Geocadin</surname><given-names>R.G.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome</article-title><source>N Engl J Med</source><volume>388</volume><issue>23</issue><year>2023</year><fpage>2171</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1056/NEJMra2114482</pub-id><pub-id pub-id-type="pmid">37285527</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Fugate</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Rabinstein</surname><given-names>A.A.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions</article-title><source>Lancet Neurol</source><volume>14</volume><issue>9</issue><year>2015</year><fpage>914</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)00111-8</pub-id><comment>[published correction appears in <italic toggle="yes">Lancet Neurol</italic>. 2015 September;14(9):874. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/S1474-4422(15)00195-7" id="interref0010">doi:10.1016/S1474-4422(15)00195-7</ext-link>]</comment><pub-id pub-id-type="pmid">26184985</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Triplett</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kutlubaev</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kermode</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>T.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome (PRES): diagnosis and management</article-title><source>Pract Neurol</source><volume>22</volume><issue>3</issue><year>2022</year><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1136/practneurol-2021-003194</pub-id><pub-id pub-id-type="pmid">35046115</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Bartynski</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Boardman</surname><given-names>J.F.</given-names></name></person-group><article-title>Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome</article-title><source>AJNR Am J Neuroradiol</source><volume>28</volume><issue>7</issue><year>2007</year><fpage>1320</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A0549</pub-id><pub-id pub-id-type="pmid">17698535</pub-id><pub-id pub-id-type="pmcid">PMC7977645</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Rabinstein</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Mandrekar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Merrell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kozak</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Durosaro</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fugate</surname><given-names>J.E.</given-names></name></person-group><article-title>Blood pressure fluctuations in posterior reversible encephalopathy syndrome</article-title><source>J Stroke Cerebrovasc Dis</source><volume>21</volume><issue>4</issue><year>2012</year><fpage>254</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2011.03.011</pub-id><pub-id pub-id-type="pmid">21536456</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Fugate</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Claassen</surname><given-names>D.O.</given-names></name><name name-style="western"><surname>Cloft</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kallmes</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Kozak</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Rabinstein</surname><given-names>A.A.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings</article-title><source>Mayo Clin Proc</source><volume>85</volume><issue>5</issue><year>2010</year><fpage>427</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.4065/mcp.2009.0590</pub-id><pub-id pub-id-type="pmid">20435835</pub-id><pub-id pub-id-type="pmcid">PMC2861971</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Liman</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Bohner</surname><given-names>G.</given-names></name><name name-style="western"><surname>Endres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>E.</given-names></name></person-group><article-title>Discharge status and in-hospital mortality in posterior reversible encephalopathy syndrome</article-title><source>Acta Neurol Scand</source><volume>130</volume><issue>1</issue><year>2014</year><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/ane.12213</pub-id><pub-id pub-id-type="pmid">24329761</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Bartynski</surname><given-names>W.S.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome, part 1: Fundamental imaging and clinical features</article-title><source>AJNR Am J Neuroradiol</source><volume>29</volume><issue>6</issue><year>2008</year><fpage>1036</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A0928</pub-id><pub-id pub-id-type="pmid">18356474</pub-id><pub-id pub-id-type="pmcid">PMC8118828</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Canney</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>M.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome in end-stage kidney disease: not strictly posterior or reversible</article-title><source>Am J Nephrol</source><volume>41</volume><issue>3</issue><year>2015</year><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1159/000381316</pub-id><pub-id pub-id-type="pmid">25871433</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="other" id="sref11"><article-title>Introduction to the HCUP National Inpatient Sample (NIS)</article-title><comment>Agency for Healthcare Research and Quality</comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp" id="intref0015">https://hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp</ext-link></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Parauda</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>Omran S.</given-names></name><etal/></person-group><article-title>Risk of stroke after posterior reversible encephalopathy syndrome</article-title><source>Stroke</source><volume>53</volume><issue>11</issue><year>2022</year><fpage>3313</fpage><lpage>3319</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.122.038673</pub-id><pub-id pub-id-type="pmid">35942880</pub-id><pub-id pub-id-type="pmcid">PMC9613524</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Alshami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Bayati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Douedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Asif</surname><given-names>A.</given-names></name></person-group><article-title>Clinical characteristics and outcomes of patients admitted to hospitals for posterior reversible encephalopathy syndrome: a retrospective cohort study</article-title><source>BMC Neurol</source><volume>21</volume><issue>1</issue><year>2021</year><fpage>107</fpage><pub-id pub-id-type="doi">10.1186/s12883-021-02143-6</pub-id><pub-id pub-id-type="pmid">33750332</pub-id><pub-id pub-id-type="pmcid">PMC7941613</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Gatla</surname><given-names>N.</given-names></name><name name-style="western"><surname>Annapureddy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sequeira</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>M.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome in systemic lupus erythematosus</article-title><source>J Clin Rheumatol</source><volume>19</volume><issue>6</issue><year>2013</year><fpage>334</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1097/RHU.0b013e3182a21ffd</pub-id><pub-id pub-id-type="pmid">23965484</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Claassen</surname><given-names>J.A.H.R.</given-names></name><name name-style="western"><surname>Thijssen</surname><given-names>D.H.J.</given-names></name><name name-style="western"><surname>Panerai</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Faraci</surname><given-names>F.M.</given-names></name></person-group><article-title>Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation</article-title><source>Physiol Rev</source><volume>101</volume><issue>4</issue><year>2021</year><fpage>1487</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1152/physrev.00022.2020</pub-id><pub-id pub-id-type="pmid">33769101</pub-id><pub-id pub-id-type="pmcid">PMC8576366</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Edvinsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Owman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sj&#246;berg</surname><given-names>N.O.</given-names></name></person-group><article-title>Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological study</article-title><source>Brain Res</source><volume>115</volume><issue>3</issue><year>1976</year><fpage>377</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(76)90356-5</pub-id><pub-id pub-id-type="pmid">184880</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Marrone</surname><given-names>L.C.P.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>Posterior reversible encephalopathy syndrome: clinical differences in patients with exclusive involvement of posterior circulation compared to anterior or global involvement</article-title><source>J Stroke Cerebrovasc Dis</source><volume>25</volume><issue>7</issue><year>2016</year><fpage>1776</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2016.03.042</pub-id><pub-id pub-id-type="pmid">27103268</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Granata</surname><given-names>G.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iannella</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Posterior reversible encephalopathy syndrome&#8212;Insight into pathogenesis, clinical variants and treatment approaches</article-title><source>Autoimmun Rev</source><volume>14</volume><issue>9</issue><year>2015</year><fpage>830</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2015.05.006</pub-id><pub-id pub-id-type="pmid">25999210</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>G.-Q.</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B.</given-names></name></person-group><article-title>Immune system activation in the pathogenesis of posterior reversible encephalopathy syndrome</article-title><source>Brain Res Bull</source><volume>131</volume><year>2017</year><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2017.03.012</pub-id><pub-id pub-id-type="pmid">28373149</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Zoccali</surname><given-names>C.</given-names></name></person-group><article-title>Endothelial dysfunction in CKD: a new player in town?</article-title><source>Nephrol Dial Transplant</source><volume>23</volume><issue>3</issue><year>2008</year><fpage>783</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfm924</pub-id><pub-id pub-id-type="pmid">18178601</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Catar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moll</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kamhieh-Milz</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-&#945; and AP-1 Signaling</article-title><source>Front Immunol</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">774052</object-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.774052</pub-id><pub-id pub-id-type="pmcid">PMC8632537</pub-id><pub-id pub-id-type="pmid">34858433</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Rizzo</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Frediani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Granata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ravasi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cusi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gallieni</surname><given-names>M.</given-names></name></person-group><article-title>Neurological complications of hemodialysis: state of the art</article-title><source>J Nephrol</source><volume>25</volume><issue>2</issue><year>2012</year><fpage>170</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.5301/jn.5000087</pub-id><pub-id pub-id-type="pmid">22241633</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Seifter</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Samuels</surname><given-names>M.A.</given-names></name></person-group><article-title>Uremic encephalopathy and other brain disorders associated with renal failure</article-title><source>Semin Neurol</source><volume>31</volume><issue>2</issue><year>2011</year><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1277984</pub-id><pub-id pub-id-type="pmid">21590619</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Ermeidi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Balafa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Spanos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zikou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Argyropoulou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siamopoulos</surname><given-names>K.C.</given-names></name></person-group><article-title>Posterior reversible encephalopathy syndrome: a noteworthy syndrome in end-stage renal disease patients</article-title><source>Nephron Clin Pract</source><volume>123</volume><issue>3-4</issue><year>2013</year><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1159/000353731</pub-id><comment>[ePub]</comment><pub-id pub-id-type="pmid">23921191</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Anne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muralidharan</surname><given-names>R.</given-names></name></person-group><article-title>Erythropoietin-associated posterior reversible encephalopathy syndrome</article-title><source>Neurologist</source><volume>26</volume><issue>3</issue><year>2021</year><fpage>98</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1097/NRL.0000000000000309</pub-id><pub-id pub-id-type="pmid">33942791</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Gungor</surname><given-names>O.</given-names></name><name name-style="western"><surname>Aydin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Inci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oguz</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Arici</surname><given-names>M.</given-names></name></person-group><article-title>Seizures in patients with kidney diseases: a neglected problem?</article-title><source>Nephrol Dial Transplant</source><volume>38</volume><issue>2</issue><year>2023</year><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfab283</pub-id><pub-id pub-id-type="pmid">34596683</pub-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Materials</title><p id="p0220">
<supplementary-material content-type="local-data" id="mmc1" position="float" orientation="portrait"><caption><title>Supplementary File (PDF)</title><p>Tables S1, S2.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.pdf" position="float" orientation="portrait"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Article Information</title><sec id="sec5"><title>Authors&#8217; Full Names and Academic Degrees</title><p id="p0190">Mingyue He, MD, and Avrum Gillespie, MD</p></sec><sec id="sec6"><title>Author Contributions</title><p id="p0195">MH and AG conceived the study, MH accessed and verified the data, MH led the data analysis with support from AG. AG oversaw the analysis. Each author contributed important intellectual content during article drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.</p></sec><sec id="sec7"><title>Support</title><p id="p0200">None.</p></sec><sec id="sec8"><title>Financial Disclosure</title><p id="p0205">Publication of this article was funded in part by the Temple University Libraries Open Access Publishing Fund.</p></sec><sec id="sec9"><title>Acknowledgements</title><p id="p0210">We extend our sincere gratitude to all the individuals who participated in this study. Their invaluable contributions were instrumental in realizing the objectives of the present research.</p></sec><sec id="sec10"><title>Peer Review</title><p id="p0215">Received January 14, 2025, as a submission to the expedited consideration track with 2 external peer reviews. Direct editorial input from an Associate Editor and the Editor-in-Chief. Accepted in revised form February 24, 2025.</p></sec></ack><fn-group><fn id="d36e3279"><p id="ntpara0010">Complete author and article information provided before references.</p></fn><fn id="appsec2" fn-type="supplementary-material"><p id="p0225">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1016/j.xkme.2025.101022" id="intref0010"><bold>Supplementary File (PDF)</bold></ext-link>
</p><p id="p0230"><bold>Table S1:</bold> ICD-10-CM Codes for Diseases and Procedures Used in the Study.</p><p id="p0235"><bold>Table S2:</bold> Regions of Hospital in NIS.</p></fn></fn-group></back></article></pmc-articleset>